Want to see JP:4884 full AI Analyst Report?
4884 Stock Chart & Stats
¥379.00
-¥48.00(-4.72%)
At close: 4:00 PM EST
¥379.00
-¥48.00(-4.72%)
Day’s Range― - ―
52-Week Range¥287.00 - ¥601.00
Previous CloseN/A
Volume217.60K
Average Volume (3M)113.88K
Market Cap
¥4.17B
Enterprise Value¥1.08K
Total Cash (Recent Filing)¥1.70B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-110.74
Shares Outstanding8,593,200
10 Day Avg. Volume130,310
30 Day Avg. Volume113,880
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)286
Revenue Forecast (FY)¥4.07B
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-free balance sheet reduces fixed financial obligations and interest-related pressure, giving the company more flexibility while it develops therapies. This can improve resilience during periods of operating losses, although declining equity limits the strength of that advantage.
Therapeutic R&D FocusA focused therapeutic-product development model gives the company a clear strategic orientation within biotechnology. Successful R&D could create valuable products and future revenue opportunities, while the specialized focus may support concentration of limited resources on pipeline development.
Existing Revenue GenerationThe company has demonstrated an ability to generate revenue, indicating some commercial activity rather than a purely pre-revenue model. That provides a foundation for future development, although the revenue base remains small and volatile and does not yet show durable expansion.
Bears Say
Persistent UnprofitabilitySustained operating and net losses show that the current business model has not converted development activity into profitable operations. Deeply negative margins reduce internal funding capacity and make future progress dependent on achieving stronger commercialization or materially improving cost economics.
Declining Revenue TrendRecent revenue contraction and volatility weaken visibility into the company’s commercial trajectory. A shrinking top line can limit reinvestment capacity, reduce operating leverage, and make it harder for fixed development costs to be absorbed as the business seeks sustainable scale.
Ongoing Cash BurnPersistent negative operating and free cash flow indicates that the company is not currently self-funding its operations. Continued cash burn can require external capital over time, increasing financing dependence and potentially limiting strategic flexibility while therapies remain under development.
Kringle Pharma, Inc. News
4884 FAQ
What was Kringle Pharma, Inc.’s price range in the past 12 months?
Kringle Pharma, Inc. lowest stock price was ¥287.00 and its highest was ¥601.00 in the past 12 months.
What is Kringle Pharma, Inc.’s market cap?
Kringle Pharma, Inc.’s market cap is ¥4.17B.
When is Kringle Pharma, Inc.’s upcoming earnings report date?
Kringle Pharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 46 days.
How were Kringle Pharma, Inc.’s earnings last quarter?
Kringle Pharma, Inc. released its earnings results on Aug 10, 2026. The company reported -¥13.07 earnings per share for the quarter.
Is Kringle Pharma, Inc. overvalued?
According to Wall Street analysts Kringle Pharma, Inc.’s price is currently Overvalued.
Does Kringle Pharma, Inc. pay dividends?
Kringle Pharma, Inc. does not currently pay dividends.
What is Kringle Pharma, Inc.’s EPS estimate?
Kringle Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kringle Pharma, Inc. have?
Kringle Pharma, Inc. has 8,593,200 shares outstanding.
What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?
Kringle Pharma, Inc. reported an EPS of -¥13.07 in its last earnings report. Following the earnings report the stock price went up 4.323%.
Which hedge fund is a major shareholder of Kringle Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4884
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kringle Pharma, Inc.
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Ribomic, Inc.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―